These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19158191)

  • 1. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients.
    Menon DV; Arbique D; Wang Z; Adams-Huet B; Auchus RJ; Vongpatanasin W
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1361-6. PubMed ID: 19158191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients.
    Raheja P; Price A; Wang Z; Arbique D; Adams-Huet B; Auchus RJ; Vongpatanasin W
    Hypertension; 2012 Aug; 60(2):319-25. PubMed ID: 22733474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative effects of chlorthalidone on sympathetic nervous system and insulin resistance in hypertensive patients may be avoided with spironolactone: further studies are still needed.
    Castro-Torres Y; Fleites-Pérez A; Carmona-Puerta R; Jiménez-Garrido RG
    Ir J Med Sci; 2015 Dec; 184(4):727-9. PubMed ID: 26341505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension.
    Wray DW; Supiano MA
    Hypertension; 2010 May; 55(5):1217-23. PubMed ID: 20368505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress.
    Yamanari H; Nakamura K; Miura D; Yamanari S; Ohe T
    Clin Exp Hypertens; 2009 Oct; 31(7):585-94. PubMed ID: 19886856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlations between blood pressure, blood volume and plasma renin during therapy with diuretics in essential hypertension. Comparison between the mineralocorticoid antagonist spironolactone and the "loop" diuretic mefruside].
    Beretta-Piccoli C; Weidmann P; de Châtel R; Hirsch D; Reubi FC
    Schweiz Med Wochenschr; 1977 Jan; 107(4):104-15. PubMed ID: 834983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrapatient comparison of treatment with chlorthalidone, spironolactone and propranolol in normoreninemic essential hypertension.
    Drayer JI; Kloppenborg PW; Festen J; van't Laar A; Benraad TJ
    Am J Cardiol; 1975 Oct; 36(5):716-21. PubMed ID: 1103606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of chlorthalidone and spironolactone in low--renin essential hypertension.
    Kreeft JH; Larochelle P; Ogilvie RI
    Can Med Assoc J; 1983 Jan; 128(1):31-4. PubMed ID: 6336600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.
    Hood SJ; Taylor KP; Ashby MJ; Brown MJ
    Circulation; 2007 Jul; 116(3):268-75. PubMed ID: 17606839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.
    Ernst ME; Carter BL; Goerdt CJ; Steffensmeier JJ; Phillips BB; Zimmerman MB; Bergus GR
    Hypertension; 2006 Mar; 47(3):352-8. PubMed ID: 16432050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximizing diuretic therapy in resistant hypertension.
    Handler J
    J Clin Hypertens (Greenwich); 2007 Oct; 9(10):802-6. PubMed ID: 17917510
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of high dose spironolactone and chlorthalidone in essential hypertension: relation to plasma renin activity and plasma volume.
    Hunyor SN; Zweifler AJ; Hansson L; Schork MA; Ellis C
    Aust N Z J Med; 1975 Feb; 5(1):17-24. PubMed ID: 1057909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone.
    Vaughan ED; Laragh JH; Gavras I; Bühler FR; Gavras H; Brunner HR; Baer L
    Am J Cardiol; 1973 Sep; 32(4):523-32. PubMed ID: 4729722
    [No Abstract]   [Full Text] [Related]  

  • 14. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A; Mahgoub M; Hall M; Feely J
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum cholesterol during treatment of hypertension with diuretic drugs.
    Ames RP; Peacock PB
    Arch Intern Med; 1984 Apr; 144(4):710-4. PubMed ID: 6712367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension.
    Mahmud A; Feely J
    Am J Hypertens; 2005 Jan; 18(1):50-5. PubMed ID: 15691617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of urinary potassium to creatinine ratio to predict diuretic response in patients with acute heart failure and preserved ejection fraction.
    Llàcer P; Núñez J; Croset F; García M; Fabregate M; Ruiz R; López G; Fernández C; Del Hoyo B; Campos J; Gomis A; Manzano L
    Clin Cardiol; 2023 Aug; 46(8):906-913. PubMed ID: 37287326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive hypotensive effect of a dihydropyridine calcium antagonist to that produced by a thiazide diuretic: a double-blind placebo-controlled crossover trial with ambulatory blood pressure monitoring.
    Stergiou GS; Malakos JS; Achimastos AD; Mountokalakis TD
    J Cardiovasc Pharmacol; 1997 Mar; 29(3):412-6. PubMed ID: 9125681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in urinary electrolytes versus serum electrolytes during treatment of primary hypertension with chlorthalidone alone and in combination with spironolactone.
    Falch DK; Schreiner AM
    Acta Med Scand; 1981; 209(1-2):111-4. PubMed ID: 7010926
    [No Abstract]   [Full Text] [Related]  

  • 20. [Is essential hypertension still a disease entity? Definition of hyporeninemic hypertension].
    Distler A
    Internist (Berl); 1974 Mar; 15(3):146-54. PubMed ID: 4600300
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.